Chamber of Commerce asks judge to block Medicare drug price negotiations before October 1

Chamber of Commerce asks judge to block Medicare drug price negotiations before October 1


The U.S. Chamber of Commerce seal is displayed during restoration at the headquarters in Washington, D.C.

Andrew Harrer | Bloomberg | Getty Images

The U.S. Chamber of Commerce on Wednesday asked a federal judge in Ohio to block Medicare’s new powers to negotiate drug prices before October 1.

The motion for a preliminary injunction is a significant escalation in the pharmaceutical industry’s legal battle against Medicare that would halt the talks before they begin this fall.

Health and Human Services Secretary Xavier Becerra will publish a list of 10 high-cost drugs by September 1 that are selected for the negotiations. Drugmakers then have to decide whether to sign agreements to participate in the talks by October 1.

The U.S. Chamber and local chambers of commerce in Dayton, Ohio and Michigan sued Medicare in federal court in the southern district of Ohio in June. They argued that the drug negotiations violate the First and Fifth Amendments of the U.S. Constitution, as well as the separation of powers.

The Chamber asked Judge Thomas Rose on Wednesday to block the negotiations before they get underway because they violate the due process clause.

Drugmaker Abbvie, a member of the U.S. Chamber and the Dayton, Ohio area chamber, fears that its blood cancer drug Imbruvica will be selected for the negotiations this fall. Imbruvica generated $4.6 billion in revenue last year, or about 8% of the company’s total sales.

CNBC Health & Science

Read CNBC’s latest health coverage:

This is a developing story. Please check back for updates.



Source

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
Health

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday.  […]

Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Health

Pfizer tops estimates, raises profit guidance even as sales fall

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Read More